Harding Loevner LP Bio N Tech Se Call Options Transaction History
Harding Loevner LP
- $17.6 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BNTX
# of Institutions
327Shares Held
39.1MCall Options Held
845KPut Options Held
1.23M-
Baillie Gifford & CO8.28MShares$944 Million0.53% of portfolio
-
Primecap Management CO Pasadena, CA4.79MShares$546 Million0.28% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.38MShares$499 Million1.49% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$216 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.15MShares$131 Million0.01% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $27.7B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...